Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial
- 28 September 2015
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 23 (2), 105-115
- https://doi.org/10.1111/jvh.12471
Abstract
Viral hepatitis is a major public health problem affecting millions of people worldwide. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The aim of the study was to assess outcomes and costs of treating patients with chronic hepatitis C in clinical practice in Germany. We carried out a prospective noninterventional study. Information on treatment outcomes, resource utilization and quality of life was provided by 281 physicians throughout Germany. Data of 3708 monoinfected HCV-patients treated between 2008 and 2011 were analysed. Therapy consisted of peginterferon/ribavirin. Mean age of patients was 43.7 years, 60.3% were male and estimated duration of infection was 13.6 years. Predominantly genotype 1 (61.3%) or 3 (28.5%) infections were observed. Sustained viral response (SVR)-rates in most frequently observed genotypes were 49.2% in GT-1 and 61.9% in GT-3 treatment-naive patients (Relapser: GT-1: 35.3% and GT-3: 57.3%; Nonresponder: GT-1: 25.0% and GT-3: 33.3%). Average treatment costs were lowest in treatment-naive patients (€18 965) and higher in patients who failed previous treatments (relapsers: €24 753; nonresponders: €19 511). Differences according to genotype were observed. Average costs per SVR in treatment-naive patients were €44 744 for GT-1 and €22 218 for GT-3. Treatment was associated with a decrease in quality of life; post-treatment quality of life was higher in patients achieving SVR. Our insight on real-life treatment outcomes and costs can serve as a reference for a comparison with other treatments. There is high need for short-term and long-term cost-effectiveness analysis in real-life settings as newly introduced treatment strategies with direct acting antivirals result in high SVR-rates but are more costly.Keywords
Funding Information
- Gilead Sciences
- Novartis
- Meso Scale Diagnostics
- AbbVie
This publication has 45 references indexed in Scilit:
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World SettingPLOS ONE, 2013
- The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countriesBMC Gastroenterology, 2013
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspectiveBMC Health Services Research, 2012
- High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 PatientsPLOS ONE, 2012
- Chronic hepatitis C: Treat or wait? Medical decision making in clinical practiceWorld Journal of Gastroenterology, 2012
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?BMC Infectious Diseases, 2010
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006